Summary & Overview
CPT 0055U: myTAIHEART™ PCR Test for Heart Transplant Rejection
CPT code 0055U is a Proprietary Laboratory Analyses (PLA) code that identifies the myTAIHEART™ laboratory test by TAI Diagnostics, Inc., a PCR-based molecular assay used alongside clinical assessment to evaluate a heart transplant recipient’s risk of rejecting a donor heart. As a PLA code, 0055U applies specifically to this single manufacturer’s test, supporting clarity in billing and tracking of this proprietary diagnostic.
Nationally, the code matters because molecular assays for transplant rejection influence clinical decision-making, utilization of immunosuppression, and downstream resource use. Payors commonly discussing coverage and payment for such assays include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. These payors shape access through coverage policies, prior authorization requirements, and coding guidance.
Readers will learn how 0055U is defined clinically and operationally, which payors are relevant for national coverage discussions, and what to expect in terms of the test’s role in transplant care pathways. The publication provides benchmarks and policy context where available, explains typical service settings, and outlines the clinical intent and application of the assay. Data not available in the input will be noted as such in corresponding sections.
Billing Code Overview
CPT code 0055U is a Proprietary Laboratory Analyses (PLA) code for the myTAIHEART™ laboratory test developed by TAI Diagnostics, Inc. The test uses PCR technology in conjunction with standard clinical assessment to help determine a heart transplant recipient’s likelihood of rejecting a donor heart.
Service Type: Proprietary laboratory molecular diagnostic test (PCR-based) for heart transplant rejection assessment
Typical Site of Service: Clinical laboratory or hospital outpatient laboratory
Clinical & Coding Specifications
Clinical Context
A 56-year-old heart transplant recipient presents for routine post-transplant surveillance. The patient is clinically stable but requires laboratory monitoring to detect early allograft rejection. The transplant cardiology team orders the 0055U myTAIHEART™ PCR-based assay performed by TAI Diagnostics, Inc., to assess the molecular signature associated with rejection risk. A peripheral whole-blood sample is collected in the outpatient transplant clinic or hospital laboratory, labeled with the patient and test identifiers, and shipped to the performing laboratory per the manufacturer's instructions. Results are returned to the transplant cardiologist and incorporated with clinical assessment, echocardiography, endomyocardial biopsy results (if available), immunosuppressive drug levels, and other laboratory data to inform surveillance and management decisions. Typical sites of service include outpatient transplant clinics, hospital inpatient units for post-operative monitoring, and specialty laboratory collection centers. Common patient clinical features prompting this test include routine surveillance after transplant, unexplained allograft dysfunction, or concern for rejection when noninvasive assessment is preferred or used adjunctively.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier applicable (placeholder) | Rarely used; default billing when no other modifier applies. |